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Abstract
Background: The risk for amenorrhea following treatment of systemic lupus erythematosus (SLE) patients with
low-dose intravenous cyclophosphamide (IVCY) has not been fully explored. Our objective was to ascertain the
incidence of amenorrhea following treatment with low-dose IVCY and the association between amenorrhea and
the clinical parameters of SLE.
Methods: A case-control retrospective study of premenopausal women ≤ 45 years old who had been treated for
SLE with low-dose IVCY (500 mg/body/pulse) plus high-dose glucocorticoids (0.8-1.0 mg/kg/day of prednisolone;
IVCY group) or glucocorticoids alone (0.8-1.0 mg/kg/day of prednisolone; steroid group) in our hospital from 2000
through 2009 was conducted using a questionnaire survey and medical record review.
Results: Twenty-nine subjects in the IVCY group and 33 subjects in the steroid group returned the questionnaire.
A multivariate analysis revealed that age at initiation of treatment ≥ 40 years old was significantly associated with
amenorrhea [p = 0.009; odds ratio (OR) 10.2; 95% confidence interval (CI) 1.8-58.7]. IVCY treatment may display a
trend for association with amenorrhea (p = 0.07; OR 2.9; 95% CI 0.9-9.4). Sustained amenorrhea developed in 4
subjects in the IVCY group and 1 subject in the steroid group; all of these patients were ≥ 40 years old. Menses
resumed in all subjects < 40 years old, irrespective of treatment.
Conclusions: Although low-dose IVCY may increase the risk for amenorrhea, our data suggest that patients < 40
years old have a minimum risk for sustained amenorrhea with low-dose IVCY treatment. A higher risk for sustained
amenorrhea following treatment with IVCY is a consideration for patients ≥ 40 years old.
Background
Systemic lupus erythematosus (SLE) remains a therapeu-
tic challenge. One of the most successful therapies for
severe SLE has been administration of monthly intrave-
nous cyclophosphamide (IVCY) for 6 months followed
by quarterly maintenance infusions for 2 years (tradi-
tional/NIH IVCY regimen) [1-3]. However, the side
effects of long-term exposure to cyclophosphamide
include infection, bone marrow damage, malignancy,
hemorrhagic cystitis, and ovarian dysfunction [2].
Ovarian dysfunction may result in physiological changes
associated with menopause, including loss of bone
mineral density, hypercholesterolemia, onset of vasomo-
tor and genitourinary symptoms, psychological distress,
weight gain, and infertility [4]. Because SLE mainly
affects premenopausal women, ovarian dysfunction is a
particularly serious adverse event in SLE and may be
particularly distressing for women who have not com-
pleted their family.
The incidence of cyclophosphamide-induced ame-
norrhea is generally related to age and cumulative
dosage of cyclophosphamide [4]. Although most data
for understanding the biological characteristics of
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oncology literature, several studies have examined
cyclophosphamide-induced amenorrhea in women
receiving traditional IVCY regimens in SLE [5-11]. In
an attempt to reduce toxicity of cyclophosphamide, a
low-dose IVCY regimen (6 fortnightly pulses at a fixed
dose of 500 mg, followed by azathioprine) was pro-
posed on the basis of the results of the Euro-Lupus
Nephritis Trial; clinical results comparable to those
obtained using the traditional regimen have been
reported [12]. However, the incidence of major side
effects did not differ significantly between the tradi-
tional and the low-dose IVCY regimen groups, perhaps
because of the low number of subjects included in the
original study [12]. Thus, the effects of low-dose IVCY
on cyclophosphamide-induced amenorrhea have not
been elucidated.
We conducted a retrospective analysis of the men-
strual function of women with SLE before and after
receiving low-dose IVCY (500 mg/pulse/month; the
duration of treatment was modified depending on clini-
cal response). The objective of this study was to gain a
better understanding of the rate of amenorrhea in pre-
menopausal women who were given low-dose IVCY
with high-dose glucocorticoid or high-dose glucocorti-
coid alone. The incidence of the resumption of menses
was also assessed. The results of this study will assist
physicians in counseling their SLE patients about the
benefits and risks of low-dose IVCY and allow women
to make better informed decisions. Improved knowledge
will also facilitate earlier intervention and treatment of
menopausal-related complications.
Methods
Patient population
We performed a case-control study of women ≤ 45
years old who were treated for active SLE with either
low-dose IVCY (500 mg/body/pulse) plus high-dose glu-
cocorticoids (0.8-1.0 mg/kg/day of prednisolone; IVCY
group) or with high-dose glucocorticoids alone (0.8-1.0
mg/kg/day of prednisolone; steroid group) at the Tokyo
Women’s Medical University hospital from 2000
through 2009. All of these patients had 4 or more
revised American College of Rheumatology (ACR) cri-
teria for SLE [13,14]. Patients who had been treated
with cyclophosphamide before this study were excluded.
One patient with pre-existing amenorrhea and 40
patients who dropped out from our follow-up were
excluded. Questionnaires about secondary amenorrhea
were sent to the remaining 72 patients. Of these, 32
patients had received low-dose IVCY treatment, and 40
had received high-dose glucocorticoid alone. Medical
records from all cases and controls were reviewed.
Treatment with glucocorticoids or immunosuppressive
drugs was instituted independent of this study. IVCY
was primarily administered for SLE patients with lupus
nephritis. Other indications for the use of IVCY
included central nervous system (CNS) syndrome, auto-
immune thrombocytopenia, autoimmune hemolytic ane-
mia, vasculitis and myositis, all of which had been
refractory to glucocorticoids. A low-dose IVCY regimen
with 500 mg/body/pulse in combination with high-dose
glucocorticoids (0.8-1.0 mg/kg/day of prednisolone) was
usually used. The duration of IVCY courses was
adjusted according to clinical response and adverse
effects. None of the women used oral or intramuscular
contraceptives during the study period. This study was
approved by the Ethical Committee of our institution,
and the Helsinki Declaration was followed throughout
the study.
Definition of amenorrhea
Amenorrhea was defined as the cessation of menses for
at least 3 consecutive months. Sustained amenorrhea
was defined as the cessation of menses for at least 12
consecutive months without resumption during the
study period. All patients with amenorrhea followed up
for at least additional 12 months to conclude on the
sustained, irreversible loss of menstruation. Hormonal
studies were not performed to support the diagnosis of
ovarian failure in the present study. The average age of
Japanese women at menopause is approximately 50
years old according to the Japan Society of Obstetrics
and Gynecology.
Data collection
The information obtained from the medical records of
subjects included demographic data (e.g., such as the
age at initiation of treatment), the clinical manifestations
of SLE, and laboratory data. The activity of SLE was
measured using the SLE Activity Index 2000 (SLEDAI-
2K) [15]. Other data about subject treatment were also
obtained from medical records, including the maximum
dose of prednisolone, the number of courses of gluco-
corticoid pulse therapy, the cumulative dose of cyclo-
phosphamide, the number of pulses of IVCY, and any
other immunosuppressants used. Information on the
subjects’ menstrual history, including development of
amenorrhea, duration of amenorrhea, resumption of
menses, time to resumption of menses, and other possi-
ble causes for amenorrhea was obtained from medical
records and returned questionnaires. Informed consent
was obtained from all participants.
Statistical analyses
The incidence of amenorrhea and the association
between amenorrhea and clinical parameters were ana-
lyzed statistically. Two-group comparisons were
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or a logistic regression analysis for categorical variables
and the Mann-Whitney U test for continuous variables.
Values of p < 0.05 were considered statistically signifi-
cant, and all tests were 2-tailed. The odds ratios (ORs)
and their 95% confidence intervals (CIs) as risks for
amenorrhea were also calculated. Finally, a stepwise
multivariate logistic regression analysis was used to
determine the risk factors for amenorrhea. All statistical
analyses were performed using JMP statistical software
(Ver. 9.0, SAS Institute, Cary, NC, USA).
Results
Characteristics of the study subjects
Ultimately, a total of 62 female subjects with SLE pro-
vided informed consent for inclusion in this study and
returned the questionnaire, representing 86% of the
number invited to participate; 29 subjects were treated
with IVCY in combination with glucocorticoids (IVCY
group), and 33 were treated with glucocorticoids alone
(steroid group). The duration of follow-up after initia-
tion of IVCY or high-dose glucocorticoid treatment ran-
g e df r o m1t o1 0y e a r s .T h es u b j e c t sw e r ea l lJ a p a n e s e .
The characteristics of the subjects are summarized in
Table 1. There was no significant difference in age, max-
imum dose of prednisolone, or the number of subjects
treated with glucocorticoid pulse therapy between the
groups. Reflecting the indications for IVCY therapy, the
SLEDAI-2K score was higher in the IVCY group than in
the steroid group (p = 0.0004). In the IVCY group, the
median cumulative dose of cyclophosphamide was 1000
mg. All subjects in both groups were successfully treated
and discharged. Although 3 subjects in the IVCY group
and 2 subjects in the steroid group later needed addi-
tional oral immunosuppressant (tacrolimus, cyclospor-
ine, or methotrexate), amenorrhea did not develop in
any of these subjects during the study period.
Azathioprine was not used in the study subjects.
Associations between amenorrhea and clinical parameters
Age at the initiation of treatment did not differ signifi-
cantly between subjects with and without amenorrhea (p
= 0.19) (Table 2). Similarly, the logistic regression analysis
did not reveal significant correlation between age and
amenorrhea (p = 0.13; OR 1.06; 95% CI 0.98-1.14). How-
ever, when all 62 study subjects were divided into two age
groups, those < 40 years old and those ≥ 40 years old at
the initiation of treatment, the univariate analyses revealed
that the highest risk for developing amenorrhea was being
≥ 40 years old (82 vs. 33%; p = 0.005; OR 9.0; 95% CI 1.7-
46.4) (Table 2). When the patients were divided into the
age groups of 32, 35, or 37 years, there was no or only
weaker statistical association (p = 0.12, 0.06, and 0.04,
respectively). In addition, from the univariate analyses, the
incidence of amenorrhea was significantly higher in the
I V C Yg r o u pt h a ni nt h es t e r o i dg r o u p( 5 9v s .2 7 % ;p =
0.02; OR 3.8; 95% CI 1.3-11.0), but the incidence of sus-
tained amenorrhea was not (14 vs. 3%; p =0 . 1 8 ) .W h e n
the total dose of cyclophosphamide was considered as a
numerical predictor variable and a univariate logistic
regression analysis was applied for all of the patients,
including patients from both the IVCY and steroid groups,
the OR was 1.0 (p = 0.08; 95% CI 1.0-1.0) for amenorrhea.
Thus, treatment with IVCY may display a trend to be
weakly associated with amenorrhea and sustained amenor-
rhea. No significant associations between amenorrhea or
sustained amenorrhea and any of the other clinical para-
meters were found in this study (summarized in Table 2).
Incidence of amenorrhea in SLE subjects by age and
treatment groups
Amenorrhea developed more frequently in subjects < 40
years old in the IVCY group than in the steroid group
(11/21 vs. 6/30; p = 0.03; OR 4.4; 95% CI 1.3-15.2)
(Table 3). Subjects ≥ 40 years old had a high incidence
of amenorrhea in both treatment groups with no statis-
tical difference between the groups (6/8 in the IVCY
group; 3/3 in the steroid group, p = 1.00) (Table 3).
Frequency of resumption of menses
There was no statistical difference in the frequency of
resumption of menses between the IVCY group and the
Table 1 Characteristics of study subjects with SLE (IVCY
group and steroid group)
IVCY group Steroid
group
p
†
n = 29 n = 33
Age (years) 31 (18-45) 30 (19-45) 0.16
Subjects < 40 years old 21 (72%) 30 (91%)
Subjects ≥ 40 years old 8 (28%) 3 (9%) 0.09
Duration of SLE (months) 7 (1-153) 2 (1-241) 0.05
SLE manifestation
Nephritis 15 (52%) 13 (39%) 0.44
CNS lupus 7 (24%) 1 (3%) 0.02
Vasculitis 5 (17%) 1 (3%) 0.09
Cytopenia 7 (24%) 10 (30%) 0.78
SLEDAI-2K 16 (2-31) 10 (3-18) 0.0004
Max. dose of prednisolone (mg) 50 (14-125) 45 (40-100) 0.79
Glucocorticoid pulse therapy 6 (20%) 6 (18%) 1.00
Total dose of cyclophosphamide
(mg)
1000 (500-
6500)
Total number of IVCY (time) 2 (1-13)
*Except where indicated otherwise, values of continuous data are the median
(range).
†p values were determined by Fisher’s exact test or Mann-Whitney U test.
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, CNS
central nervous system, SLEDAI-2K systemic lupus erythematosus disease
activity index 2000.
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(Table 4). In the patients with transient amenorrhea,
time to resumption of menses was 8 (3-18) months in
the IVCY group and 6 (3-12) months in the steroid
group, respectively (median and range, respectively):
there was no statistical difference (p = 0.91). The logistic
regression analysis revealed a significant correlation
between age and sustained amenorrhea (p < 0.0001).
Sustained amenorrhea developed in 4 subjects in the
IVCY group and in 1 subject in the steroid group; all of
these subjects were > 40 years old. Conversely, menses
resumed in all subjects < 40 years old in both treatment
groups. Thus, menses resumed more frequently in sub-
jects < 40 years old than in the subjects > 40 years old
(p = 0.002) (Table 4). Unfortunately, the small sample
size of our study hampered the power to statistically
evaluate any significant association of IVCY with sus-
tained amenorrhea in the both age groups.
Multivariate analysis of risk for amenorrhea
Using a stepwise multiple regression analysis, a signifi-
cant association between amenorrhea and being ≥ 40
years old was found (p = 0.009; OR 10.2; 95% CI 1.8-
58.7) (Table 5). Treatment with IVCY may show a trend
to be weakly associated with amenorrhea (p = 0.07; OR
2.9; 95% CI 0.9-9.4). In addition, when the total dose of
cyclophosphamide was considered as a numerical pre-
dictor variable, and a similar multivariate logistic regres-
sion analysis was applied for all of the patients,
including patients from both the IVCY and steroid
groups, the OR of IVCY was 1.0 (95% CI 1.0-1.0; p =
0.11) for amenorrhea. The multivariate analysis of
Table 2 Comparisons of clinical parameters of SLE patients with and without amenorrhea
With amenorrhea Without amenorrhea p
† OR
‡ (95% CI)
n = 26 n = 36
Age (years) 33 (18-45) 30 (19-44) 0.20 1.0 (1.0-1.1)
Subjects < 40 years old 17 (65%) 34 (94%) 0.005 9.0 (1.7-46.4)
Subjects ≥ 40 years old 9 (35%) 2 (6%)
Duration of SLE (months) 5 (1-241) 3 (1-128) 0.77 1.0 (1.0-1.0)
SLE manifestation
Nephritis 12 (46%) 16 (44%) 1.00 1.1 (0.4-3.0)
CNS lupus 5 (19%) 3 (8%) 0.26 2.6 (0.6-12.1)
Vasculitis 2 (8%) 4 (11%) 1.00 0.7 (0.1-3.9)
Cytopenia 8 (31%) 9 (25%) 0.77 1.3 (0.4-4.1)
Positive anti-SS-A/Ro antibodies 14 (54%) 21 (58%) 0.80 0.8 (0.3-2.3)
Positive anti-U1-RNP antibodies 10 (38%) 16 (44%) 0.61 0.7 (0.3-1.9)
SLEDAI-2K 13.5 (5-31) 11.5 (2-26) 0.35 0.9 (0.9-1.0)
Max. dose of prednisolone (mg) 50 (25-125) 45 (14-100) 0.43 1.0 (1.0-1.0)
Glucocorticoid pulse therapy 6 (23%) 6 (17%) 0.54 1.5 (0.4-5.3)
IVCY 17 (65%) 12 (33%) 0.02 3.8 (1.3-11.0)
Total dose of cyclophosphamide (mg) 1300 (500-6500) 1000 (500-2700) 0.69 -
Total number of IVCY (time) 2 (1-13) 2.5 (1-5) 1.00 -
*Except where indicated otherwise, values of continuous data are the median (range). Total dose of IVCY and total number of IVCY were calculated with the
subjects in the IVCY group only.
†p values were determined by Fisher’s exact test or Mann-Whitney U test.
‡ORs of numerical valuables were determined by univariate logistic regression.
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, OR odds ratio, CI confidence interval, CNS central nervous system, SLEDAI-2K systemic
lupus erythematosus disease activity index 2000.
Table 3 Incidence of amenorrhea in SLE patients in each
age and treatment group
With
amenorrhea
Without
amenorrhea
p*O R
(95% CI)
n=2 6 n=3 6
Age < 40 years
old
IVCY
group
†
11 (42%) 10 (28%) 0.03 4.4 (1.3-
15.2)
Steroid
group
†
6 (23%) 24 (67%) - -
Age ≥ 40 years
old
IVCY
group
†
6 (23%) 2 (6%) 1.00 -
Steroid
group
†
3 (12%) 0 (0%) - -
*p values were determined by Fisher’s exact test.
†Patients with SLE were divided into 2 groups: those who received low-dose
IVCY plus high-dose glucocorticoids (IVCY group) and those who received
high-dose glucocorticoids alone (steroid group).
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, OR
odds ratio, CI confidence interval.
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overall low incidence yielded insufficient numbers for
analysis.
Other adverse events
Major potentially IVCY-related adverse events in the
study subjects are summarized in Table 6. The inci-
dence of adverse events other than amenorrhea was low,
and no significant differences between the IVCY group
and the steroid group were found.
Discussion
The important findings of this study are that i) patients
< 40 years old have a minimum risk for sustained ame-
norrhea with low-dose IVCY treatment; ii) irrespective
of treatment regimen, sustained amenorrhea developed
frequently in patients ≥ 40 years old at initiation of
treatment; iii) even low-dose IVCY may increase the risk
of transient amenorrhea; and iv) the strongest risk factor
for developing amenorrhea in SLE patients treated with
high-dose glucocorticoids with or without low-dose
IVCY is being ≥ 40 years old at the initiation of
treatment.
The low-dose IVCY treatment regimen was initially
proposed as an attempt to reduce the toxicity of cyclo-
phosphamide [12]. However, the incidence of major side
effects, including menopause, did not differ significantly
between traditional and low-dose IVCY regimen groups
(menopause; 2/45 and 2/44, respectively) in the original
study [12]. Although patients treated with high-dose or
traditional IVCY regimens were not included in the pre-
sent study, the proportion of sustained amenorrhea in
patients < 40 years old in our study (0/51) was much
lower than similar figures for patients treated with the
traditional IVCY regimen in other studies. At initiation
of traditional IVCY therapy, Boumpas et al. reported
that sustained amenorrhea developed in 19% (6/31) of
women ≤ 30 years old [5], Mok et al. reported that sus-
tained amenorrhea developed in 19% (10/54) of women
<4 0y e a r so l d[ 7 ] ,P a r ke ta l .r e p o r t e dt h a ts u s t a i n e d
Table 4 Comparisons of menses resumption by age or treatment regimen groups
Resumed menses Sustained amenorrhea p*O R
† (95% CI)
n=2 1 n=5
Treatment regimen
IVCY group
‡ 13 (62%) 4 (80%) 0.63 2.5 (0.2-26.1)
Steroid group
‡ 8 (38%) 1 (20%) -
Age
< 40 years old 17 (81%) 0 (0%) 0.002 -
≥ 40 years old 4 (19%) 5 (100%) -
Age < 40 years old
IVCY group
‡ 11 (52%) 0 (0%) 1.00 -
Steroid group
‡ 6 (29%) 0 (0%) -
Age ≥ 40 years-old
IVCY group
‡ 2 (10%) 4 (80%) 0.52 4.0 (0.2-75.7)
Steroid group
‡ 2 (10%) 1 (20%) -
*p values were determined by Fisher’s exact test.
†ORs were defined as the ratios of the odds of sustained amenorrhea.
‡Patients with SLE were divided into 2 groups: those who received low-dose IVCY plus high-dose glucocorticoids (IVCY group) and those who received high-dose
glucocorticoids alone (steroid group).
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, OR odds ratio, CI confidence interval.
Table 5 Multivariate analysis of associations between
clinical parameters and amenorrhea
Clinical parameter p* OR* (95% CI)
Age ≥ 40 years old 0.009 10.2 (1.8 - 58.7)
IVCY 0.07 2.9 (0.9 - 9.4)
Maximum dose of prednisolone 0.10 1.0 (1.0 - 1.1)
*p values and ORs were determined by stepwise multivariate logistic
regression using a model adjusted for the following variables: ‘Age ≥ 40
years-old’; IVCY; maximum dose of prednisolone; steroid pulse therapy;
SLEDAI-2K.
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, OR
odds ratio, CI confidence interval.
Table 6 Major adverse events in study subjects with SLE
Adverse events* IVCY group Steroid group
n=2 9 n=3 3
Amenorrhea 17 (59%) 9 (27%)
Elevation of liver enzymes 2 (7%) 0 (0%)
Hematological disorder 1 (3%) 0 (0%)
Herpes Zoster infection 1 (3%) 2 (6%)
Cytomegalovirus infection 0 (0%) 1 (3%)
Tinea corporis 0 (0%) 1 (3%)
Myocarditis 1 (3%) 0 (0%)
*Adverse events that are usually not regarded as IVCY-related are excluded
from this table.
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus.
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years old [8], and Ioannidis et al. reported that sustained
amenorrhea developed in 11% (5/44) of women ≤ 31
years old [11]. Thus, when considering the benefits of
low-dose IVCY and the risk for amenorrhea, treatment
with low-dose IVCY would have a lower risk for sus-
tained amenorrhea than higher-dose regimens and
should be well tolerated in premenopausal patients < 40
years old. In addition, previous reports demonstrate that
the rates of amenorrhea following short-term high-dose
IVCY are also lower than those following long-term
high-dose IVCY: 0-12% [5,8,10]. Because our IVCY pro-
tocol in the present study was mostly both low-dose
and short-term, the duration of IVCY treatment and
cumulative dose of cyclophosphamide also affect the
resumption of menses. However, our study shows that
even low-dose IVCY may increase the risk of transient
amenorrhea, an important clinical consideration that
should not be overlooked.
Consistent with previous studies using the traditional
IVCY regimen [5,7,8,11] and with breast cancer studies
[4,16], sustained amenorrhea developed frequently in
patients ≥ 40 years old at initiation of treatment, irrespec-
tive of treatment regimen. The strongest risk factor for
developing amenorrhea in SLE patients treated with high-
dose glucocorticoids with or without low-dose IVCY was
being ≥ 40 years old at the initiation of treatment in the
present study. Older women are more likely to progress to
premature ovarian failure after therapy because they have
a smaller number of oocytes at the initiation of treatment
[17]. Thus, the higher risk of sustained amenorrhea from
IVCY therapy should be a serious consideration in patients
> 40 years old. In addition, when the patients were divided
into the age groups of 32, 35, or 37 years, there was no or
only weaker statistical association, although there might
be an increasing risk for amenorrhea after the age of 35
years. Age at the initiation of treatment did not differ sig-
nificantly between subjects with and without amenorrhea,
and the logistic regression analysis did not reveal signifi-
cant correlation between age and amenorrhea. Thus, we
speculate that the age of 40 was a threshold for the
patients in the present study.
Cyclophosphamide toxicity in women may arise from
direct effects on the oocyte, or indirectly through its
effects on the supporting granulosa cells of the follicle
through gap junctions connecting these “nursing cells”
to the oocyte [17]. DNA cross-linking occurs in granu-
losa cells of animals treated with cyclophosphamide
within 2 hours of administration, as well as increased
nuclear size, which is thought to result from a cell-cycle
block in G2 phase [17]. Following exposure to cyclopho-
sphamide, human ovaries are fibrosed, and follicles are
destroyed [17]. Ovarian dysfunction can be partially
mitigated during IVCY therapy by using gonadotrophic-
releasing hormone analogues, which reduce proliferation
within the ovary [17]. However, the risk of precipitating
a disease flare with hormonal stimulation must be con-
sidered when treating SLE [17].
One of the limitations of the present study is the
selection bias inherent in a single-center retrospective
study, although rarity of the disease makes performing
prospective studies difficult. In addition, our subject
number was insufficient for definitive conclusions about
association between amenorrhea and low-dose IVCY,
and we lacked controls such as age-matched healthy
subjects or SLE patients who were not treated with glu-
cocorticoids. However, the size of our study population
is comparable to similar previously reported studies, and
treatment without glucocorticoids in active SLE is
impractical. Another potential weakness arises from the
lack of uniformity of the follow-up duration and treat-
ment regimens, although all study subjects were fol-
lowed up for at least 1 year, usually sufficient time to
evaluate drug-induced amenorrhea and menses resump-
tion. Evaluation of ovarian function could not be
included because we did not measure the hormone
levels of all of the subjects. The fact that the SLEDAI-
2K score was higher in the IVCY group compared with
the steroid group may be a limitation of this study
because high disease activity has previously been asso-
ciated with the development of amenorrhea in SLE [18].
However, in the present study, there was no association
between the SLEDAI-2K score and amenorrhea. Finally,
because this study was not designed to assess the effec-
tiveness of low-dose IVCY, it is not clear whether our
low-dose IVCY regimen is applicable to severe manifes-
tations of SLE. Considering that the patients that could
not respond to the questionnaire due to severe or fatal
disease were excluded from the study and that some of
the study subjects required additional therapy, our low-
dose IVCY regimen would not necessarily be suitable
for all severe manifestations of SLE.
In conclusion, SLE patients < 40 years old have a
minimum risk for sustained amenorrhea with low-dose
IVCY treatment, whereas higher-dose IVCY reportedly
has a higher risk even in this younger population. In
contrast, sustained amenorrhea developed frequently in
patients ≥ 40 years old at the initiation of treatment;
this higher risk of sustained amenorrhea with IVCY
therapy requires serious consideration when treating
SLE patients ≥ 40 years old. However, our study demon-
strates the possibility that even low-dose IVCY may
increase the risk of amenorrhea, an important clinical
consideration that should not be overlooked.
Conclusions
Although low-dose IVCY may increase the risk for ame-
norrhea, our data suggest that patients < 40 years old
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low-dose IVCY treatment. A higher risk for sustained
amenorrhea following treatment with IVCY is a consid-
eration for patients ≥ 40 years old.
Acknowledgements
We thank Dr. Eisuke Inoue (Institute of Rheumatology, Tokyo Women’s
Medical University) for assisting with statistical analyses.
Authors’ contributions
SB and YKatsumata conceived the study and drafted the manuscript.
YKawaguchi, TG, TS and TK participated in acquisition of data and patient
recruitment. MH and HY participated in the design and coordination of the
study. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 February 2011 Accepted: 10 June 2011
Published: 10 June 2011
References
1. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J,
Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and
cyclophosphamide, alone or in combination, in patients with lupus
nephritis. A randomized, controlled trial. Ann Intern Med 1996,
125(7):549-557.
2. Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS: High-dose
cyclophosphamide versus monthly intravenous cyclophosphamide for
systemic lupus erythematosus: a prospective randomized trial. Arthritis
Rheum 2010, 62(5):1487-1493.
3. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A,
Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J:
Controlled clinical trial of IV cyclophosphamide versus IV
methylprednisolone in severe neurological manifestations in systemic
lupus erythematosus. Ann Rheum Dis 2005, 64(4):620-625.
4. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R: The rates of
chemotherapy-induced amenorrhea in patients treated with adjuvant
doxorubicin and cyclophosphamide followed by a taxane. Am J Clin
Oncol 2007, 30(2):126-132.
5. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE:
Risk for sustained amenorrhea in patients with systemic lupus
erythematosus receiving intermittent pulse cyclophosphamide therapy.
Ann Intern Med 1993, 119(5):366-369.
6. Langevitz P, Klein L, Pras M, Many A: The effect of cyclophosphamide
pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol
1992, 28(3):157-158.
7. Mok CC, Lau CS, Wong RW: Risk factors for ovarian failure in patients
with systemic lupus erythematosus receiving cyclophosphamide
therapy. Arthritis Rheum 1998, 41(5):831-837.
8. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK: Risk of ovarian
failure and pregnancy outcome in patients with lupus nephritis treated
with intravenous cyclophosphamide pulse therapy. Lupus 2004,
13(8):569-574.
9. Appenzeller S, Blatyta PF, Costallat LT: Ovarian failure in SLE patients using
pulse cyclophosphamide: comparison of different regimes. Rheumatol Int
2008, 28(6):567-571.
10. Laskari K, Zintzaras E, Tzioufas AG: Ovarian function is preserved in
women with severe systemic lupus erythematosus after a 6-month
course of cyclophosphamide followed by mycophenolate mofetil. Clin
Exp Rheumatol 2010, 28(1):83-86.
11. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM: Predictors of
sustained amenorrhea from pulsed intravenous cyclophosphamide in
premenopausal women with systemic lupus erythematosus. J Rheumatol
2002, 29(1):2129-2135.
12. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R,
Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, et al:
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis
Trial, a randomized trial of low-dose versus high-dose intravenous
cyclophosphamide. Arthritis Rheum 2002, 46(8):2121-2131.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG,
Talal N, Winchester RJ: The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1982, 25(1):1271-1277.
14. Hochberg MC: Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 1997, 40(9):1725.
15. Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus
disease activity index 2000. J Rheumatol 2002, 29(2):288-291.
16. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal
women treated with adjuvant chemotherapy for breast cancer. J Clin
Oncol 1996, 14(5):1718-1729.
17. Pendse S, Ginsburg E, Singh AK: Strategies for preservation of ovarian and
testicular function after immunosuppression. Am J Kidney Dis 2004,
43(5):772-781.
18. Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II: Ovarian function and
disease activity in patients with systemic lupus erythematosus. Clin Exp
Rheumatol 2008, 26(3):436-441.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6874/11/28/prepub
doi:10.1186/1472-6874-11-28
Cite this article as: Baba et al.: Association between low-dose pulsed
intravenous cyclophosphamide therapy and amenorrhea in patients
with systemic lupus erythematosus: A case-control study. BMC Women’s
Health 2011 11:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baba et al. BMC Women?’?s Health 2011, 11:28
http://www.biomedcentral.com/1472-6874/11/28
Page 7 of 7